Elisabeth O. R.
- Country
- Norway
- Department
- Children and Youth Clinica, Pediatric oncology/hematology unit
Research Overview
- Interfant-21: International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia
- Evaluation of Quizartinib in Combination with Chemotherapy for Pediatric FLT3-ITD Positive, NPM1 Wild-Type Acute Myeloid Leukemia
- Evaluation of Gemtuzumab Ozogamicin and Drug Combination in Pediatric Acute Myeloid Leukemia: A NOPHO-DB-SHIP Consortium Study
Data & Insights
Has run more than one trial at 78 of 178 partner sites.
Specializations
Pediatric Hematologic Oncology
This investigator specializes in treating blood cancers in children and adolescents, with particular focus on acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
- Advanced AML Treatment Protocols
- Infant Leukemia Management
- Early Disease Response Assessment
The investigator's work encompasses developing treatment strategies for infants under one year of age and optimizing therapeutic approaches for adolescents with various forms of leukemia.
Therapeutic Innovation
Focused on advancing treatment protocols for childhood leukemia, incorporating novel therapeutic agents and treatment combinations to enhance patient outcomes.
- Risk-Stratified Treatment Approaches
- Consolidation Therapy Optimization
- Treatment Protocol Development
The investigator evaluates innovative therapeutic strategies aimed at improving survival rates while minimizing treatment burden.
Specialized Leukemia Care
Expertise in treating distinct molecular subtypes of leukemia, including KMT2A-rearranged infant ALL and CD33-positive AML.
- Molecular-Based Treatment Selection
- Age-Specific Therapeutic Approaches
- Treatment Response Monitoring
The investigator's practice focuses on tailoring treatments based on specific genetic and molecular characteristics of leukemia.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.